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Dear Editor: Imatinib mesylate (Gleevec; Novartis AG, Basel, Switzerland), a selective tyrosine receptor kinase inhibitor, is increasingly used for treating chronic myeloid leukemia, Philadelphia chromosome-positive acute lymphoblastic leukemia, and high-grade gastrointestinal stromal tumors (GISTs) 1 . Several cases of cutaneous reactions after imatinib use have been reported 1 . We report a case of EM after imatinib administration for the treatment of a GIST.
A 66-year-old woman was referred for pruritus from the department of oncology. She received a diagnosis of a GIST, for which she received adjuvant imatinib therapy after gastric wedge resection. She noticed a pruritic rash on her trunk after 5 weeks of 400 mg/day imatinib therapy. Physical examination revealed generalized variable-sized erythematous wheal-like patches with some targetoid lesions on the trunk, face, and extremities ( Fig. 1) . Immunoglobulin (Ig) G and IgM antibodies to the herpes simplex virus were not detected. A skin biopsy from the trunk revealed vacuolar degeneration, tagging of lymphocytes along the dermal-epidermal junction, and perivascular lymphocytic and some eosinophilic infiltrations in the upper dermis ( Fig. 2A) . Some dyskeratotic and necrotic keratinocytes were obvious in the epidermis (Fig. 2B) ; therefore, EM was diagnosed. As imatinib was the only medication administered to the patient, it was considered the most probable cause. Imatinib was discontinued, and oral steroid and antihistamine were prescribed. For 2 weeks, 30 mg/day steroid, tapered to 5 mg/day, was administered. One month after the discontinuation of imatinib therapy, the rash was fully cured. Imatinib treatment was restarted at a lower dose of 100 mg/day without steroids; no skin lesion developed for 2 months. However, when the dose Here, we observed a case of imatinib-induced EM. We noted a dose-dependent relation; thus, we consider that imatinib-induced EM is related to a pharmacological effect of imatinib. The skin lesion subsided and did not recur only with the concomitant use of low-dose oral steroids. As imatinib is a very effective therapeutic agent and alternative treatment options are limited, recognition of adverse cutaneous reactions after imatinib therapy and the appropriate management required is helpful.
A Giant, Deep, Benign Fibrous Histiocytoma with a Palisading Pattern
Jeong Nan Kang, Wonkyung Lee, So Young Jung A 42-year-old male patient presented to our clinic with a skin-colored mass that had been present for 2 years; his medical and family histories were otherwise unremarkable. Physical examination revealed a soft, movable, skin-colored mass on his upper left back, with a brown, bean-sized pedunculated nodule on the overlying skin (Fig. 1A) . Excisional biopsy was performed. The tumor, which was well demarcated and localized in the subcutaneous layer, measured 5.4×5.1×2.1 cm (Fig. 1B) . The histopathological examination indicated that the lesion was an encapsulated mass, located in subcutaneous tissue with a central cavity. The tumor was well-circumscribed by a fibrous capsule, and no honeycomb pattern was observed in the marginal area. In the tumor periphery, large blood vessels with a dilated, branching appearance were observed (Fig. 2A) . The tumor cells were arranged in a palisading and partially storiform pattern, with focal myxoid change (Fig. 2B) . Under high magnification, the tumor cells were spindle shaped with elongated nuclei and an ill-defined cytoplasm; individual cells were infiltrating between collagen bundles and arranged in a palisading pattern, similar to Verocay bodies (Fig. 2C) . Cellular atypia and mitotic bodies were not detected. Immunohistochemical analysis revealed that the cells were strongly positive for CD34 (Fig. 2D) ; focally positive for factor XIIIa; and negative for S-100 (Fig. 2E) , desmin, actin, and CD68. A diagnosis of giant, deep, benign fibrous histiocytoma (BFH), with a palisading pattern, was rendered, with no evidence of recurrence at 15 months after excision. BFH, which is characterized by several histological subtypes, is among the most-common soft tissue skin tumors. Since Fletcher's 1 description in 1990 of 21 cases of deep BFH (DBFH), several more cases have been reported [1] [2] [3] .
